Off-Label Ltd

subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

US search results

Number of records found 7

Select ID for details Off-label therapeutic category Subcategory Drug Reported off-label use
4858 Central Nervous System Cognitive Raloxifene hydrochloride Multicentre, three year study to investigate whether raloxifene (60 mg daily or 120 mg daily) reduces the risk of developing dementia and cognitive impairment (secondary outcome) among postmenopausal women with osteoporosis (Since raloxifene is licensed in this population for the treatment and prevention of osteoporosis, the primary study outcome, the effect of raloxifene upon vertebral fractures is within the scope of the Label)
1060 Endocrine & Metabolic Pituitary-gonadal axis Raloxifene hydrochloride To explore the effects upon serum lipids, pituitary-gonadal axis, prostate and bone turnover in healthy elderly men (High dose)
1061 Endocrine & Metabolic Pituitary Raloxifene hydrochloride To assess efficacy in treating male patients with active acromegaly (High dose)
2455 Malignant Disease Breast Raloxifene hydrochloride Modulation of plasma levels of Insulin-like growth factor 1 (IGF-1) and leptin in premenopausal females at high risk for developing invasive breast cancer (changes in levels of IGF-1 and leptin may be associated with the risk of developing breast cancer)
9017 Musculoskeletal & Joint Fibromyalgia Raloxifene hydrochloride Randomized controlled trial to compare the efficacy of raloxifene (60 mg on alternate days for sixteen weeks) with that of placebo in a total of one hundred menopausal women with fibromyalgia (The investigators report that raloxifene produced a significantly higher response rate than placebo with an improvement in pain and fatigue, a reduction in the tender point count, reduced sleep disturbance, and a recovery of usual activities)
2456 Obstetrics & Gynecology (incl male infertility) Uterus Raloxifene hydrochloride To inhibit the growth of uterine leiomyomas in premenopausal females
3533 Obstetrics & Gynecology (incl male infertility) Uterus Raloxifene hydrochloride To evaluate the effectiveness of raloxifene plus leuprorelin for the treatment of premenopausal women with symptomatic uterine leiomyomas

Definition of descriptors (where appropriate):

*The reported drug was used as part of a combined therapy regimen

SUBPOP Variability in response may represent responding/nonresponding patient subgroups
ALERT Potential for remarkable and/or significant toxicity

 

 

 

About Us |Privacy Policy | Contact Us | ©2008 Off-Label Ltd